share_log

Hoth Therapeutics Announces FDA Acceptance Of IND Application For HT-001 For Treatment Of Cancer Disorders Associated With Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Hoth Therapeutics Announces FDA Acceptance Of IND Application For HT-001 For Treatment Of Cancer Disorders Associated With Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Hoth Therapeutics 宣布美国食品药品管理局接受用于治疗与表皮生长因子受体 (EGFR) 抑制剂疗法相关的癌症疾病的 HT-001 的临床申请
Benzinga Real-time News ·  2022/12/29 08:47

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for the company's HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer.

以患者为中心的生物制药公司Hoth Therapeutics, Inc.（纳斯达克股票代码：HOTH）今天宣布，美国食品药品监督管理局（FDA）已接受该公司用于治疗与表皮生长因子受体（EGFR）抑制剂疗法相关的皮疹和皮肤疾病的 HT-001 疗法的研究性新药（IND）申请。表皮生长因子抑制剂是治疗非小细胞肺癌 (NSCLC)、胰腺癌、结直肠癌、头颈部鳞状细胞癌和乳腺癌的关键治疗药物。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发